Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 8/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27889697 | 0.84 | ERN1 (0.57) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL30973586 | 0.83 | ERN1 (0.55) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL28293621 | 0.82 | ERN1 (0.68) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL31551028 | 0.82 | ERN1 (0.53) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL6413771 | 0.82 | ERN1 (0.53) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL415808 | 0.81 | ERN1 (0.51) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL14292141 | 0.81 | ERN1 (0.51) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL20196192 | 0.81 | ERN1 (0.53) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL6090664 | 0.80 | ERN1 (0.51) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL5883425 | 0.80 | KDM4E (0.66) | ERN1ALDH1A1KDM4ETSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113666812-B | Synthesis method of 5-halogenated veratraldehyde | 四川大学 | 2022-06-24 | — | — | CN | disclosed |
| CN-113735847-B | Synthetic preparation method of berberine hydrochloride | 四川大学 | 2022-06-07 | — | — | CN | disclosed |
| CN-113735847-A | Synthetic preparation method of berberine hydrochloride | 四川大学 | 2021-12-03 | — | — | CN | disclosed |
| CN-113666812-A | Synthesis method of 5-halogenated veratraldehyde | 四川大学 | 2021-11-19 | — | — | CN | disclosed |
| EP-2794620-B1 | BODIPY STRUCTURE FLUORESCENCE PROBES FOR DIVERSE BIOLOGICAL APPLICATIONS | NAT UNIV SINGAPORE (SG) | 2017-11-15 | — | — | EP | disclosed |
| US-9423395-B2 | Fluorescent cell cycle probe having M-phase specificity | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-08-23 | — | — | US | disclosed |
| US-9423396-B2 | Bodipy structure fluorescence probes for diverse biological applications | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-08-23 | — | — | US | disclosed |
| US-9423395-B2 | Fluorescent cell cycle probe having M-phase specificity | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-08-23 | — | — | US | disclosed |
| US-9423396-B2 | Bodipy structure fluorescence probes for diverse biological applications | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-08-23 | — | — | US | disclosed |
| US-20150355168-A1 | FLUORESCENT CELL CYCLE PROBE HAVING M-PHASE SPECIFICITY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-12-10 | — | — | US | disclosed |
| EP-2103596-A1 | Process for the preparation of N-(phenylethyl) anilines salts and solvates thereof useful as serotonin 5-HT6 antagonists | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-09-23 | — | — | EP | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1856075-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | Epix Delaware, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
| EP-1687641-A2 | TREATING NEUROPATHIC PAIN WITH NEUROPEPTIDE FF RECEPTOR 2 AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006081332-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | EPIX DELAWARE, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| US-20050136444-A1 | Treating neuropathic pain with neuropeptide FF receptor 2 agonists | ACADIA PHARMACEUTICALS INC. | 2005-06-23 | — | — | US | disclosed |
| WO-2005031000-A2 | TREATING NEUROPATHIC PAIN WITH NEUROPEPTIDE FF RECEPTOR 2 AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-4963590-A | ENZYME INHIBITOR FOR TREATING PARKINSON'S DISEASE ALONG WITH DOPA;POTENTIATION | ORION-YHTYMA OY (FI) | 1990-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | ERN1 4404/4885ALDH1A1 1488/4885KDM4E 1616/4885 |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | ERN1 988/4885ALDH1A1 1587/4885KDM4E 2123/4885 |
| US-20150355168-A1 | FLUORESCENT CELL CYCLE PROBE HAVING M-PHASE SPECIFICITY | CCNB1, BOD1L1, CCNB3 | ERN1 2128/4885ALDH1A1 3833/4885KDM4E 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.